Holen Sie sich die Stockscreener-App
163.48
0.46%
-0.7295
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$164.21
Offen:
$164.47
24-Stunden-Volumen:
584.17K
Relative Volume:
0.18
Marktkapitalisierung:
$253.52B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
49.10
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
+0.07%
1M Leistung:
+0.46%
6M Leistung:
-15.70%
1J Leistung:
+113.05%
1-Tages-Spanne:
$162.95
$164.48
1-Wochen-Bereich:
$162.91
$167.52
52-Wochen-Spanne:
$80.48
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
163.47 | 258.35B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,184.21 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.49 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.27 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.29 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
144.58 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca PLC Agencies, 2026 - OpenSecrets
Directors’ Deals: AstraZeneca’s Soriot in a major show of faith - Financial Times
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca Gets FDA Priority Review for IMFINZI Combo - grafa.com
AstraZeneca & Fevertree Drinks: Big director share deals - Investors' Chronicle
AstraZeneca gains EU approval for asthma drug, boosting growth outlook with strong pipeline and oncology focus - Pluang
Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum (NYSE:AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Wins EU Asthma Nod For Trixeo This Week: How Big Is Respiratory Opportunity? - Kalkine Media
AstraZeneca hails US priority review for Imfinzi for bladder cancer - London South East
AstraZeneca stock slips 1.91 percent as earnings estimates rise - AD HOC NEWS
Priority review for AstraZeneca's Imfinzi in bladder cancer - marketscreener.com
AstraZeneca stock gains 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca stock rises 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca PLC Agencies, 2021 - OpenSecrets
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? - Yahoo Finance
AstraZeneca’s New Asthma Care Trial Signals Long-Term Upside for Respiratory Investors - TipRanks
AstraZeneca stock heads into the open after a 2.84 percent drop - AD HOC NEWS
AstraZeneca stock heads into the open after a 1.20 percent drop - ad-hoc-news.de
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AstraZeneca stock falls 2.65 percent after the close - AD HOC NEWS
AstraZeneca wins EU label expansion for Trixeo in asthma (AZN) - Seeking Alpha
AstraZeneca slides Wednesday, underperforms market - MarketWatch
AstraZeneca's Trixeo Secures Approval for Asthma in the EU - Yahoo Finance Australia
AstraZeneca LSE:AZN EU Drug Wins Put Cancer and Autoimmune Growth in Focus - kalkinemedia.com
AstraZeneca stock slips as Trixeo wins EU asthma approval - AD HOC NEWS
EU clears first triple-therapy asthma medicine from AstraZeneca (AZN) - Stock Titan
AstraZeneca (LSE:AZN) Pipeline Wins Put Valuation in Focus - Kalkine Media
AstraZeneca wins EU approval for Trixeo asthma inhaler - proactiveinvestors.co.uk
AstraZeneca PLC Announces Trixeo Approved In EU For Asthma - TradingView
AstraZeneca’s Trixeo Aerosphere Approved In EU For Asthma - DirectorsTalk Interviews
REGAstraZeneca PLCTrixeo approved in EU for asthma - TradingView
AstraZeneca stock heads into the open after a 0.08 percent fall - AD HOC NEWS
AstraZeneca stock gains 1.22 percent at the close - AD HOC NEWS
BreakingviewsCOMMENTARY: Big Pharma growth malady has a risky cure - Reuters
AstraZeneca stock gains as Deutsche Bank raises its target - AD HOC NEWS
AZN Historical Stock Prices & Daily Price Data | AstraZeneca PLC - Quiver Quantitative
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England - Insider Monkey
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Is A 27.75% Upside On The Horizon? - DirectorsTalk Interviews
Two favorable EU opinions for AstraZeneca - marketscreener.com
AstraZeneca’s Klygefa Recommended For EU Approval In Generalised Myasthenia Gravis - DirectorsTalk Interviews
AstraZeneca PLC (AZN.L) Stock Analysis: Unveiling a 26% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca PLC (Dinari Tokenized Stock)AZNStock Price & News - The Motley Fool
AstraZeneca PLC Agencies, 2024 - opensecrets.org
Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial - insights.citeline.com
AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer - marketscreener.com
AstraZeneca (AZN) CEO buys 60,000 shares in LON trade - Stock Titan
FDA Grants Priority Review to AstraZeneca's Efzimfotase - marketscreener.com
AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug - marketscreener.com
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer - AstraZeneca
AstraZeneca Wins US FDA Priority Review for Hypophosphatasia Therapy - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):